In the tumor microenvironment, CAFs secrete FGF5, which activates FGFR2–Nrf2–HO-1 signaling, thereby reducing cisplatin-induced ferroptosis and contributing to resistance [41]. Here, NFE2L2 is linked to neoplasm.